Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Promising Procedure Injects Stem Cells Directly Into Patientâ??s Heart

Posted Dec 10 2008 11:30am 1 Comment

In a ground-breaking procedure, surgeons at The Methodist Hospital in Houston injected highly concentrated stem cells directly into a patient’s heart, providing an intense, direct hit on damaged heart tissue.

This technique may be more successful in regenerating healthy heart tissue than current methods that use a catheter to put standard stem cells through the bloodstream into the heart. The 58-year old patient is expected to be discharged this weekend.

“Some patients have such severe heart failure that their only current option is a heart transplant,” said Dr. Brian Bruckner, cardiac surgeon at the Methodist DeBakey Heart & Vascular Center in Houston. “We hope that stem cells will stimulate angiogenesis, the growth of new blood vessels, restore mechanical function in diseased heart tissue, and return patients to a much better quality of life without a transplant.”

In a novel process, the patient’s strongest and most robust stem and progenitor cells, derived from the patient’s own bone marrow, are amplified up to 1,000 times before they’re injected back into the patient’s heart. In the procedure, Dr. Bruckner made a small incision in the left side of the patient’s chest and administered approximately 25 injections of concentrated stem cells into the patient’s heart. All patients in the trial will be followed for 12 months after the injections.

There are currently 5.5 million people in the U.S. suffering from chronic heart failure. A subset of these patients has dilated cardiomyopathy (DCM), a chronic heart disease in which the patient's heart can not pump effectively enough to deliver blood and oxygen to the vital organs in the body. Patients with DCM typically experience severe limitations to physical activity and shortness of breath.

“Without a new approach to treatment of these patients, they will continue to decline and less than 40 percent will survive five years,” said Bruckner, principal investigator for the trial. “We hope this trial will provide a completely new and viable treatment for them.”

Dr. Michael Reardon, chief of cardiac surgery at Methodist, and Dr. Matthias Loebe, transplant surgeon at Methodist, are co-investigators on the trial. Dr. Kevin Lisman is the patient’s referring cardiologist.

Source: Methodist Hospital, Houston, Texas, November 20, 2008

Comments (1)
Sort by: Newest first | Oldest first

BioHeart recently completed an identical treatment at its new stem cell therapy for CHG Center of Excellence at Hospital Angeles Tijuan. Principle investigator is Warren Sherman, M.D., of Columbia University Medical Center's Stem Cell Research Institute.   Dr. Sherman says, "I have come to believe that valuable knowledge can be gained from small-to-moderate sized clinical studies conducted outside of the US.  Depending on objectives and design, the costs and logistics of certain studies can be burdensome, or even prohibitive to conduct in the US.  The two key points here are, first and foremost, to ensure the rights and safety of patients, wherever a clinical trial is done. And secondly, that data arising from the study be complete and transparent. Without both elements in-place, a study will unlikely add to our knowledge of stem cell repair, or advance the field. To my eyes, Bioheart's initiative ensures that the integrity of both treatment and data collection is preserved, and I anticipate the scientific community will eagerly follow the program's progress." 

 

 

Here is the link:  (http://www.miamiherald.com/2010/04/14/1579506/bioheart-commenced-successful.html)

Post a comment
Write a comment: